|
Use of homologous recombination deficiency (HRD) score to enrich for niraparib sensitive high grade ovarian tumors. |
|
|
Employment - Amgen (I); Tesaro |
Stock and Other Ownership Interests - Tesaro |
Patents, Royalties, Other Intellectual Property - Tesaro |
|
|
No Relationships to Disclose |
|
|
Employment - Myriad Genetics |
Stock and Other Ownership Interests - Myriad Genetics |
Research Funding - Myriad Genetics |
|
|
Employment - Myriad Genetics |
Stock and Other Ownership Interests - Myriad Genetics |
Research Funding - Myriad Genetics |
|
|
Employment - Myriad Genetics (I) |
Stock and Other Ownership Interests - Myriad Genetics |
Research Funding - Myriad Genetics |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Tesaro |
Research Funding - Tesaro |
Patents, Royalties, Other Intellectual Property - Tesaro |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Myriad Genetics (I) |
Stock and Other Ownership Interests - Myriad Genetics |
|
|
|
Stock and Other Ownership Interests - Tesaro |
|
|
Employment - Myriad Genetics |
Stock and Other Ownership Interests - Myriad Genetics |
Research Funding - Myriad Genetics |
|
|
Honoraria - Boehringer Ingelheim |
Consulting or Advisory Role - Boehringer Ingelheim |
Research Funding - Clovis Oncology; Genentech; MedImmune; Merck (Inst); Nektar; Tesaro |
Travel, Accommodations, Expenses - Boehringer Ingelheim |